OSU-03012 and viagra treatment inhibits the activity of multiple chaperone proteins and disrupts the blood-brain barrier: Implications for anti-cancer therapies

Journal of Cellular Physiology

Volumn 230, Issue 8, 2015, Pages 1982-1998

  Booth, Laurence ^a   Roberts, Jane L ^a   Tavallai, Mehrad ^a   Nourbakhsh, Aida ^a   Chuckalovcak, John ^b   Carter, Jori ^c   Poklepovic, Andrew ^c   Dent, Paul ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b BIO RAD LABORATORIES   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; ACTIVATING TRANSCRIPTION FACTOR 4; BREAST CANCER RESISTANCE PROTEIN; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INITIATION FACTOR 2ALPHA; JANUS KINASE 1; JANUS KINASE 2; LAPATINIB; MULTIDRUG RESISTANCE PROTEIN 1; SILDENAFIL; SORAFENIB; ANTINEOPLASTIC AGENT; CHAPERONE; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; SMALL INTERFERING RNA; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANIMAL; BRAIN TUMOR; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; HUMANS; MICE; MOLECULAR CHAPERONES; PIPERAZINES; PURINES; PYRAZOLES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928382653     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24977     Document Type: Article

References (69)

1. Anderson K, Stott EJ, Wertz GW. 1992. Intracellular processing of the human respiratory syncytial virus fusion glycoprotein: Amino acid substitutions affecting folding, transport and cleavage. J Gen Virol 73:1177-1188.
2. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, Ko MK, Bayan JA, Sacapano MR, Espinoza A, Irvin DK, Shu Y. 2008. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 1230:290-302.
3. Bolt G. 2001. The measles virus (MV) glycoproteins interact with cellular chaperones in the endoplasmic reticulum and MV infection upregulates chaperone expression. Arch Virol 146:2055-2068.
4. Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, Grant S, Dent P. 2012b. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biol Ther 13:224-236.
5. Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P. 2012a. OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biol Ther 13:1501-1511.
6. Booth L, Roberts JL, Conley A, Cruickshanks N, Ridder T, Grant S, Poklepovic A, Dent P. 2014d. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biol Ther 15:305-316.
7. Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, Fisher PB, Kukreja RC, Grant S, Poklepovic A, Dent P. 2014c. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol 85:408-419.
8. Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P. 2014a. Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. Mol Cancer Ther 13:2384-2398.
9. Booth L, Roberts JL, Cruickshanks N, Tavallai S, Webb T, Samuel P, Conley A, Binion B, Young HF, Poklepovic A, Spiegel S, Dent P. 2014b. PDE5 inhibitors enhance celecoxib killing in multiple tumor types. J Cell Physiol 230:1115-1127.
10. Carleton M, Brown DT. 1997. The formation of intramolecular disulfide bridges is required for induction of the Sindbis virus mutant ts23 phenotype. J Virol 71:7696-7703.
11. Chen WT, Zhu G, Pfaffenbach K, Kanel G, Stiles B, Lee AS. 2014. GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN. Oncogene 33:4997-5005.
12. Choi CY, Park KR, Lee JH, Jeon YJ, Liu KH, Oh S, Kim DE, Yea SS. 2007. Isoeugenol suppression of inducible nitric oxide synthase expression is mediated by down-regulation of NF-kappaB, ERK1/2, and p38 kinase. Eur J Pharmacol 576:151-159.
13. Cui W. Yu CH Hu KQ. 2005. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clin Cancer Res 11:8213-8221.
14. Das A, Xi L, Kukreja RC. 2008. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283:29572-29585.
15. Deguchi A, Thompson WJ, Weinstein IB. 2004. Activation of protein kinase G is sufficient to induce apoptosis and inhibit cell migration in colon cancer cells. Cancer Res 64:3966-3973.
16. Dimcheff DE, Faasse MA, McAtee FJ, Portis JL. 2004. Endoplasmic reticulum (ER) stress induced by a neurovirulent mouse retrovirus is associated with prolonged BiP binding and retention of a viral protein in the ER. J Biol Chem 279:33782-33790.
17. Donnelly N, Gorman AM, Gupta S, Samali A. 2013. The eIF2α kinases: Their structures and functions. Cell Mol Life Sci 70:3493-3511.
18. Earl PL, Moss B, Doms RW. 1991. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol 65:2047-2055.
19. Friebe A, Koesling D. 2009. The function of NO-sensitive guanylyl cyclase: What we can learn from genetic mouse models. Nitric Oxide 21:149-156.
20. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. 2005. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164-176.
21. Gorbatyuk MS, Gorbatyuk OS. 2013. The molecular chaperone GRP78/BiP as a therapeutic target for neurodegenerative disorders: A mini review. J Genet Syndr Gene Ther 4: pii: 128. PMCID: 3674464.
22. Ha KS, Kim KM, Kwon YG, Bai SK, Nam WD, Yoo YM, Kim PK, Chung HT, Billiar TR, Kim YM. 2003. Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation. FASEB J 17:1036-1047.
23. Hayden MA, Lange PA, Nakayama DK. 2001. Nitric oxide and cyclic guanosine monophosphate stimulate apoptosis via activation of the Fas-FasL pathway. J Surg Res 101:183-189.
24. He B. 2006. Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ 13:393-403.
25. Hogue BG, Nayak DP. 1992. Synthesis and processing of the influenza virus neuraminidase, a type II transmembrane glycoprotein. Virology 188:510-517.
26. Johnson AJ, Smith LL, Zhu J, Heerema NA, Jefferson S, Mone A, Grever M, Chen CS, Byrd JC. 2005. A novel celecoxib derivative, OSU-03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase-and Bcl-2-independent mechanism. Blood 105:2504-2509.
27. Kang SG, Kim JS, Park K, Kim JS, Groves MD, Nam DH. 2006. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol Rep 15:7-13.
28. Karami-Tehrani F, Moeinifard M, Aghaei M, Atri M. 2012. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res 43:470-475.
29. Kashfi K, Rigas B. 2005. Is COX-2 a 'collateral' target in cancer prevention? Biochem Soc Trans 33:724-727.
30. Kato M, Blanton R, Wang GR, Judson TJ, Abe Y, Myoishi M, Karas RH, Mendelsohn ME. 2012. Direct binding and regulation of RhoA by cyclic GMP-dependent protein kinase Iα. J Biol Chem 287:41342-41351.
31. Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A. 2006. The selective Cox-2 inhibitor celecoxib suppresses angiogenesis and growth of secondary bone tumors: An intravital microscopy study in mice. BMC Cancer 12:6-9.
32. Koehne CH Dubois RN. 2004. COX-2 inhibition and colorectal cancer. Semin Oncol 31:12-21.
33. Komalavilas P, Shah PK, Jo H, Lincoln TM. 1999. Activation of mitogen-activated protein kinase pathways by cyclic GMP and cyclic GMP-dependent protein kinase in contractile vascular smooth muscle cells. J Biol Chem 274:34301-34309.
34. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS. 2004. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 64:1444-1451.
35. Lee AS. 2007. GRP78 induction in cancer: Therapeutic and prognostic implications. Cancer Res 67:3496-3499.
36. Lin YG, Shen J, Yoo E, Liu R, Yen HY, Mehta A, Rajaei A, Yang W, Mhawech-Fauceglia P, DeMayo FJ, Lydon J, Gill P, Lee AS. 2015. Targeting the glucose-regulated protein-78 abrogates Pten-null driven AKT activation and endometrioid tumorigenesis. Oncogene, DOI: 10.1038/onc.2015.4 [Epub ahead of print].
37. Liu R, Li X, Gao W, Zhou Y, Wey S, Mitra SK, Krasnoperov V, Dong D, Liu S, Li D, Zhu G, Louie S, Conti PS, Li Z, Lee AS, Gill PS. 2013. Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis. Clin Cancer Res 19:6802-6811.
38. Luo B, Lee AS. 2013. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 32:805-818.
39. Maurel M, Chevet E, Tavernier J, Gerlo S. 2014. Getting RIDD of RNA: IRE1 in cell fate regulation. Trends Biochem Sci 39:245-254.
40. Moreno JA, Tiffany-Castiglioni E. 2014. The chaperone Grp78 in protein folding disorders of the nervous system. Neurochem Res 40:329-335.
41. Narayanan BA, Narayanan NK, Pittman B, Reddy BS. 2006. Adenocarcina of the mouse prostate growth inhibition by celecoxib: Downregulation of transcription factors involved in COX-2 inhibition. Prostate 66:257-265.
42. Panner A, Murray JC, Berger MS, Pieper RO. 2007. Heat shock protein 90 alpha recruits FLIPS to the death-inducing signaling complex and contributes to TRAIL resistance in human glioma. Cancer Res 67:9482-9489.
43. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, Calderwood SK, Sherman MY, Koumenis C, Spiegel S, Chen CS, Graf M, Curiel DT, Fisher PB, Grant S, Dent P. 2008. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol 73:1168-1184.
44. Patel MI, Subbaramaiah K, Du B, Chang M, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ. 2005. Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11:1999-2007.
45. Potter LR. 2011. Guanylyl cyclase structure, function and regulation. Cell Signal 23:1921-1926.
46. Rao R, Fiskus W, Ganguly S, Kambhampati S, Bhalla KN. 2012. HDAC inhibitors and chaperone function. Adv Cancer Res 116:239-262.
47. Rathore APS, Ng ML, Vasudevan SG. 2013. Differential unfolded protein response during Chikungunya and Sindbis virus infection: CHIKV nsP4 suppresses eIF2α phosphorylation. Virol J 10:36.
48. Reid SP, Shurtleff AC, Costantino JA, Tritsch SR, Retterer C, Spurgers KB, Bavari S. 2014. HSPA5 is an essential host factor for Ebola virus infection. Antiviral Res 109:171-174.
49. Roberts JL, Booth L, Conley A, Cruickshanks N, Malkin M, Kukreja RC, Grant S, Poklepovic A, Dent P. 2014. PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biol Ther 15:758-767.
50. Roller C, Maddalo D. 2013. The molecular chaperone GRP78/BiP in the development of chemoresistance: Mechanism and possible treatment. Front Pharmacol 4:10.
51. Roux L. 1990. Selective and transient association of Sendai virus HN glycoprotein with BiP. Virology 175:161-166.
52. Sano R, Reed JC. 2013. ER stress-induced cell death mechanisms. Biochim Biophys Acta 1833:3460-3470.
53. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, Binet JL, Delic J, Merle-Beral H. 2003. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 101:265-269.
54. Shan X, Quaile MP, Monk JK, French B, Cappola TP, Margulies KB. 2012. Differential expression of PDE5 in failing and nonfailing human myocardium. Circ Heart Fail 5:79-86.
55. Shen Y, Meunier L, Hendershot LM. 2002. Identification and characterization of a novel endoplasmic reticulum (ER) DnaJ homologue, which stimulates ATPase activity of BiP in vitro and is induced by ER stress. J Biol Chem 277:15947-15956.
56. Spurgers KB, Alefantis T, Peyser BD, Ruthel GT, Bergeron AA, Costantino JA, Enterlein S, Kota KP, Boltz RC, Aman MJ, Delvecchio VG, Bavari S. 2010. Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen. Mol Cell Proteomics 9:2690-2703.
57. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D, Pamukcu R. 2000. Exisulind induction of apoptosis involves guanosine 3', 5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 60:3338-3342.
58. Tong L, Heim RA, Wu S. 2011. Nitric oxide: A regulator of eukaryotic initiation factor 2 kinases. Free Radic Biol Med 50:1717-1725.
59. Tsai YL, Zhang Y, Tseng CC, Stanciauskas R, Pinaud F, Lee AS. 2015. Characterization and mechanism of stress-induced translocation of 78-kilodalton glucose regulated protein (GRP78) to the cell surface. J Biol Chem pii: jbc.M114.618736 [Epub ahead of print].
60. Xu A, Bellamy AR, Taylor JA. 1998. BiP (GRP78) and endoplasmin (GRP94) are induced following rotavirus infection and bind transiently to an endoplasmic reticulum-localized virion component. J Virol 72:9865-9872.
61. Xu Z, Jensen G, Yen TS. 1997. Activation of hepatitis B virus S promoter by the viral large surface protein via induction of stress in the endoplasmic reticulum. J Virol 71:7387-7392.
62. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. 2006. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 70:589-603.
63. Zhang X, Yan G, Ji J, Wu J, Sun X, Shen J, Jiang H, Wang H. 2012. PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. J Cell Biochem 113:2738-2743.
64. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble JW, Shiau CW, et al. 2004. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64:4309-4318.
65. Zhu B, Strada SJ. 2007. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem 7:437-454.
66. Zhu B, Strada S, Stevens T. 2005a. Cyclic GMP-specific phosphodiesterase 5 regulates growth and apoptosis in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 289:L196-L206.
67. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ. 2005b. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94:336-350.
68. Zhu B, Zhang L, Alexeyev M, Alvarez DF, Strada SJ, Stevens T. 2009. Type 5 phosphodiesterase expression is a critical determinant of the endothelial cell angiogenic phenotype. Am J Physiol Lung Cell Mol Physiol 296:L220-L228.
69. Zusman RM, Morales A, Glasser DB, Osterloh IH. 1999. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 83:35C-44C.